N.v. Nutricia

Nutricia N.v.

Other

Robert Johan Joseph Hageman

Patrick Joseph Gerardus Hendrikus Kamphuis

Amanda Johanne Kiliaan

Martine Groenendijk

Mattheus Cornelis De Wilde

Adrianus Lambertus Bertholdus Van Helvoort

Klaske Van Norren

Jacob Geert Bindels

Rudolf Leonardus Lodewijk Smeets

Joyce Faber

George Verlaan

Arjan Paul Vos

Hobbe Friso Smit

Ladislaus Maria Broersen

Chantal Nelleke Kleijer

Maud Goethals

Eline Marleen Van Der Beek

Albertus Dominicus Marcellinus Erasmus Osterhaus

Katrien Maria Jozefa Van Laere

Houkje Bouritius

Natalie Elizabeth Hotrum

Nick Van Wijk

Roelof Andre Bork

Gelske Speelmans

Antonie Van Baalen

Wynette Hermina Agnes Kiers

Gilda Elise Georgi

Evan Abrahamse

Adrianus Johannes Maria Vriesema

Zandrie Hofman

Alexander Josephus Maricus Van Puijenbroek

Maria Anna Verheul-Koot

Mirian Lansink

Carla Angèle Paula Buijsse

Johannes Wilhelmus Christina Sijben

Marchel Gorselink

Yvo Maria Franciscus Graus

Cornelus Johannes Petrus Van Limpt

Esther Jacqueline De Kort

G&uuml;nther Sawatzki

Sofia Lopes Da Silva

Erwin Peke Meijer

Jan Albertus Boerma

Ceirwen Jane Green

Danielle Stefanie Counotte

Arie Nieuwenhuizen

Regine Patricia Maria Steegers-Theunissen

Mehmet Cansev

G&uuml;nther Boehm

Roelof André Bork

Liliane Marie-Rose Louisa Dominique Dumon

Peti Huybers

Jan Maarten Verkuijl

Chantal Severijnen

Hubertus Josephus Maria Van De Heijning

John Cowper Kingston Wells

Liliane Marie-Rosé Liuisa Dominique Dumon

Klaske Anna Van Hoey-De Boer

Wendy Antoinette Verwillegen

Raelene Butler

Hubertus Josephus Van De Heijning

John Sijben

Myryam Rakhshandehroo

Paul Johannes Maria Savelkoul

The invention pertains to the use of soluble sodium in the manufacture of a composition or kit of parts for (therapeutically) improving and prolonging blood plasma uridine levels and tissue availability of uridine, and/or for treating or preventing impaired blood plasma uridine levels and tissue availability of uridine, and/or for preventing/treating disorders associated with impaired blood plasma and tissue availability of uridine, in a mammal, preferably a human being, by orally co-administering soluble sodium and uridine in a molar ratio of soluble sodium to uridine of more than 1:1, preferably more than 1.5:1, more preferably more than 2:1, even more preferably at least 2.5:1, even more preferably at least 2.8:1, more preferably 3:1-15:1, most preferably 3:1-10:1, particularly 3:1-5:1.

Method for increasing uridine concentration in blood plasma

The invention provides for an enteral nutritional composition comprising (a) a lipid fraction, (b) a digestible carbohydrate fraction and (c) a protein fraction, wherein the lipid fraction comprises therapeutically effective amounts of (i) DHA and optionally EPA, and (ii) medium-chain triglycerides, preferably at least 2 wt % C8 and C10 medium-chain triglycerides based on weight of the fatty acids; and wherein the composition has a ketogenic weight ratio between 1.4:1 and 3:1, for use in the treatment of traumatic brain injury (TBI).

Treatment of traumatic brain injury

The invention pertains to the use of therapeutically effective amounts of (i) vitamin A and/or functional equivalents, (ii) vitamin D and/or functional equivalents, and (iii) at least one omega-3 PUFA, preferably DHA and/or EPA, more preferably DHA and EPA, for the manufacture of a composition or medicament for treating, reducing and/or preventing neuroinflammation and/or symptoms associated with neuroinflammation in a subject in need thereof, as well as for reducing microglia activation, and/or for treating, reducing and/or preventing symptoms associated with excessive activation of microglia; and/or for reducing the secretion of inflammatory cytokines, preferably IL-6, and/or for treating, reducing and/or preventing symptoms associated with excessive secretion of inflammatory cytokines, in a subject in need thereof.

Method for controlling neuroinflammation

The invention pertains to the use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a composition for treating, preventing or reducing the risk of occurrence of white matter lesions, white matter hyperintensities (WMH), Leukoaraiosis or periventricular white matter disease in elderly not suffering from a neurodegenerative disorder, preferably non-demented elderly and elderly not suffering from Alzheimer's Disease. It was found that with the compositions according to the invention Nogo-A protein levels could be controlled, particularly suppressed or reduced.

Method for reducing white matter lesions, white matter hyperintensities (WMH), leukoaraiosis or periventricular white matter disease in elderly

The invention relates to a nutritional composition comprising

Nutritional composition for improving the mammalian immune system

The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of &#x3b1;-linolenic acid (ALA), calculated on the weight of all fatty acids;iii) choline, or salts or esters thereof;for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.

Method for treating neurotrauma

This invention pertains to the use of an uridine source, preferably uridine monophosphate, for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8 &#x3bc;M in a subject in need thereof, comprising administering to said subject a composition comprising 300-900 mg of said uridine source daily for a period of at least 4 weeks. In particular, the use of an uridine source is intended forelderly and/or subjects suffering from neurological disorders such as Alzheimer's Disease and dementia syndromes.

Product and method for supporting uridine homeostasis

The invention relates to a nutritional composition comprising (a) at least 18 en % of proteinaceous matter, said proteinaceous matter comprising whey; (b) at least 12 wt % of leucine, based on total proteinaceous matter; and (c) a lipid fraction comprising at least a &#x3c9;-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid for improving the muscle function in a mammal, for improving daily activity, for improving physical performance, for providing a better prognosis in terms of extended life-expectancy, for improving compliance to an anti-cancer therapy or for improving a quality of life.

Nutritional composition for improving muscle function and daily activity

The invention relates to the use of specific protein and/or peptide fractions having a high aspartate content for regulating plasma glucose concentrations and increasing insulin sensitivity in a mammal. The invention relates to a complete food fortified with aspartate equivalents as well as a supplement rich in aspartate equivalents that is given simultaneously with or even minutes up to an hour prior to the consumption of a meal comprising glucose. The nutritional or pharmaceutical composition contains at least one protein having a high aspartate content, preferably of soy or dairy origin, which is further enriched with aspartate equivalents from another protein and/or free aspartate equivalents. The protein fraction comprises glutamate equivalents in a weight ratio of aspartate equivalents to glutamate equivalents (asp:glu) between 0.41:1 and 5:1.

Preparation for use of aspartate for regulating glucose levels in blood

The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a reduction in bone mineral density in a subject or for in vivo regulating of the blood plasma calcium homeostasis.

Combination of a leucine source and an omega-3 unsaturated fatty acid source for use in the treatment of hypercalcaemia

The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B 12 and precursors thereof, vitamin B6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of a preparation for improving the action of receptors. This preparation is advantageously applied in patients suffering from Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and ADHD.

Preparation for improving the action of receptors

The invention relates to a nutritional composition comprising dietary fiber, a peptide having 7 or more amino acid units, the nutritional composition comprising a tryptophan source, which may be said peptide or different there from, for use in the treatment of a negative emotion or introvert behavior. The invention further relates to a combination of dietary fiber, a peptide having 7 or more amino acid units, the nutritional composition comprising a tryptophan source, which may be said peptide or different there from, and optionally one or more other components, for use in the treatment of a negative emotion or introvert behavior.

Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour

Non-medical use of at least two components selected from the group of: (i) nucleoside equivalents, (ii) n-3 polyunsaturated fatty acids selected from the group of DHA, DPA and EPA, (iii) vitamins B, (iv) phospholipids, (v) antioxidants and (vi) cholines&#x2014;with the proviso that at least one (i) nucleoside or at least one (iii) vitamin B is present&#x2014;for increasing or maintaining the body weight, for improving the ability to perform an activity of daily living of a mammal, for maintaining the ability to perform an activity of daily living of a mammal, or for reducing a deterioration in the ability to perform an activity of daily living of a mammal.

Non-medical increase or maintenance of body weight of a mammal

The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of &#x25a1;-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.

Growing community of inventors

Wageningen, Netherlands

Robert Johan Joseph Hageman